Abstract
Novel treatment strategies and new information concerning the management of moderate to severe psoriasis justify a reassessment of the role of the classic therapies in this setting. This consensus statement evaluates narrowband UV-B therapy, which is currently considered the phototherapy option of choice in psoriasis because of its risk-to-benefit ratio. The role of excimer laser and photodynamic therapies are also discussed. These targeted therapies are still only available in a small number of centers in Spain and are used principally in the treatment of localized and recalcitrant forms of psoriasis. We discuss the efficacy and safety of phototherapy as well as treatment regimens, combination therapy, and clinical considerations relating to the characteristics of the patient or the disease.
Copyright © 2010 Elsevier España, S.L. y AEDV. All rights reserved.
Publication types
-
Consensus Development Conference
-
Practice Guideline
MeSH terms
-
Acitretin / therapeutic use
-
Adrenal Cortex Hormones / administration & dosage
-
Adrenal Cortex Hormones / therapeutic use
-
Adult
-
Child
-
Clinical Trials as Topic
-
Combined Modality Therapy
-
Comorbidity
-
Contraindications
-
Erythema / etiology
-
Female
-
Humans
-
Lasers, Excimer / adverse effects
-
Lasers, Excimer / therapeutic use*
-
Low-Level Light Therapy / adverse effects
-
Low-Level Light Therapy / methods*
-
Neoplasms, Radiation-Induced / etiology
-
Neoplasms, Radiation-Induced / prevention & control
-
PUVA Therapy / adverse effects
-
PUVA Therapy / methods
-
Photochemotherapy / adverse effects
-
Photochemotherapy / methods*
-
Pregnancy
-
Pregnancy Complications / radiotherapy
-
Psoriasis / drug therapy
-
Psoriasis / radiotherapy
-
Psoriasis / therapy*
-
Radiotherapy Dosage
-
Ultraviolet Therapy / adverse effects
-
Ultraviolet Therapy / methods*
Substances
-
Adrenal Cortex Hormones
-
Acitretin